[Outcomes and prognostic factors of advanced XXXX after concurrent chemoradiotherapy].

@entity1 @entity6461 @entity5 @entity957 @entity900 @entity1349
OBJECTIVE: To evaluate the outcomes and the prognostic factors for advanced @entity5 after concurrent chemoradiotherapy (CCRT). METHODS: Totally 172 @entity1 with International Federation of Gynecology and Obstetrics stage IIb-IV who were treated in Cancer Hospital, Chinese Academy of Medical Sciences between January 2007 and December 2008 were retrospectively analyzed. @entity1 were received external radiotherapy, high-dose rate brachytherapy and @entity900 -based chemotherapy concurrently. RESULTS: The median follow-up period was 54.5 months. The 2-year and 5-year @entity1349 ( @entity1349 ) were separately 81.5% and 68.8%. The 2-year and 5-year progress-free survival (PFS) were separately 69.2% and 63.1%. Using univariate analysis followed with multivariate analysis, the results showed that these clinicopathological factors including stage (III and above versus IIb; P = 0.021, HR = 1.95; P = 0.020, HR = 1.86), maximum diameter of local @entity5 size (>4 versus  <= 4 cm; P = 0.009, HR = 2.55; P = 0.033, HR = 1.94), @entity957 antigen ( @entity6461 ) level before treatment (>3 versus  <= 3   g/L; P = 0.010, HR = 2.47; P = 0.013, HR = 2.09) and retroperitoneal lymph node status on imaging (para-aortic lymph node positive versus negative, P = 0.009, HR = 3.00, P = 0.010, HR = 2.74; pelvic lymph node positive only versus negative, P = 0.044, HR = 1.98, P = 0.033, HR = 1.92) had the significant effect on @entity1349 and PFS. @entity1 with no above adverse prognostic factor were assigned to Group A (n = 18), those with one factor were assigned to Group B (n = 43), and those with no less than two factors were assigned to Group C (n = 111). Among three groups, the 2-year @entity1349 were separately 94.1%, 97.7% and 73.1%, the 5-year @entity1349 were separately 81.4%, 90.1% and 58.6%, the 2-year PFS were separately 88.2%, 90.4% and 57.9%, the 5-year PFS were 82.4%, 87.9% and 50.0%. The results showed that group C was significant difference from Group A or B in @entity1349 and PFS (all P < 0.05), while Group A had no significant difference from Group B in @entity1349 and PFS (P > 0.05). CONCLUSIONS: Stage III or above, maximum diameter of local @entity5 size >4 cm, @entity6461 level >3   g/L before treatment and positive retroperitoneal lymph nodes on imaging are four independent adverse factors for prognosis of @entity5 of advanced stage after CCRT. The treatment of @entity1 with no less than two adverse factors should be considered to be improved.
